Spyre Therapeutics Added to the Nasdaq Biotechnology Index
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on Inflammatory Bowel Disease (IBD) treatment, has announced its addition to the Nasdaq Biotechnology Index (NBI), effective December 23, 2024. The inclusion comes as part of the NBI's annual evaluation process. Companies must meet specific eligibility criteria including minimum market capitalization, average daily trading volume, and public company seasoning requirements. The NBI tracks performance of biotechnology and pharmaceutical securities listed on Nasdaq and operates under a modified capitalization-weighted methodology.
Spyre Therapeutics (NASDAQ: SYRE), un'azienda biotecnologica in fase clinica focalizzata sul trattamento della Malattia Infiammatoria Intestinale (IBD), ha annunciato la sua inclusione nel Nasdaq Biotechnology Index (NBI), a partire dal 23 dicembre 2024. Questa inclusione è parte del processo di valutazione annuale del NBI. Le aziende devono soddisfare specifici criteri di idoneità che includono una capitalizzazione di mercato minima, un volume di scambi giornaliero medio e requisiti di maturità per le società quotate. Il NBI monitora le performance dei titoli biotecnologici e farmaceutici quotati su Nasdaq e opera secondo una metodologia di capitalizzazione ponderata modificata.
Spyre Therapeutics (NASDAQ: SYRE), una empresa biotecnológica en fase clínica centrada en el tratamiento de la Enfermedad Inflamatoria Intestinal (IBD), ha anunciado su inclusión en el Índice de Biotecnología de Nasdaq (NBI), que entrará en vigor el 23 de diciembre de 2024. La inclusión forma parte del proceso de evaluación anual del NBI. Las empresas deben cumplir con criterios específicos de elegibilidad, que incluyen una capitalización de mercado mínima, un volumen medio de negociación diario y requisitos de madurez para empresas públicas. El NBI rastrea el rendimiento de los valores biotecnológicos y farmacéuticos listados en Nasdaq y opera bajo una metodología de capitalización ponderada modificada.
Spyre Therapeutics (NASDAQ: SYRE), 임상 단계의 생명공학 회사로 염증성 장질환 (IBD) 치료에 집중하고 있으며, 2024년 12월 23일부로 나스닥 생명공학 지수 (NBI)에 추가될 것이라고 발표했습니다. 이 추가는 NBI의 연례 평가 프로세스의 일환으로 이루어집니다. 기업은 최소 시장 자본화, 평균 일일 거래량 및 상장 기업 성숙도 요구 사항을 포함한 특정 적격 기준을 충족해야 합니다. NBI는 나스닥에 상장된 생명공학 및 제약 증권의 성과를 추적하며 수정된 자본화 가중 방법론에 따라 운영됩니다.
Spyre Therapeutics (NASDAQ: SYRE), une entreprise biopharmaceutique en phase clinique spécialisée dans le traitement de la Maladie Inflammatoire de l'Intestin (IBD), a annoncé son inclusion dans le Nasdaq Biotechnology Index (NBI), effective le 23 décembre 2024. Cette inclusion fait partie du processus d'évaluation annuel du NBI. Les entreprises doivent respecter des critères d'éligibilité spécifiques, notamment une capitalisation boursière minimale, un volume de transactions quotidien moyen et des exigences de maturité pour les entreprises cotées. Le NBI suit la performance des titres biotechnologiques et pharmaceutiques cotés sur la Nasdaq et fonctionne selon une méthodologie de pondération en capitalisation modifiée.
Spyre Therapeutics (NASDAQ: SYRE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung von Entzündlichen Darmerkrankungen (IBD) konzentriert, hat seine Aufnahme in den Nasdaq Biotechnology Index (NBI) bekannt gegeben, die am 23. Dezember 2024 in Kraft tritt. Die Aufnahme erfolgt im Rahmen des jährlichen Bewertungsprozesses des NBI. Unternehmen müssen bestimmte Zulassungskriterien erfüllen, darunter eine mindestens erforderliche Marktkapitalisierung, ein durchschnittliches tägliches Handelsvolumen und Anforderungen an die Reifung des Unternehmens. Der NBI verfolgt die Leistung von biotechnologischen und pharmazeutischen Wertpapieren, die an der Nasdaq gelistet sind, und arbeitet nach einer modifizierten kapitalisierungsgewichteten Methodik.
- Addition to Nasdaq Biotechnology Index increases visibility and potential institutional investment interest
- Company meets NBI's stringent eligibility requirements, indicating strong market presence
- None.
The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology.
For more information about the Nasdaq Biotechnology Index, please visit this link.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn
View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-added-to-the-nasdaq-biotechnology-index-302334852.html
SOURCE Spyre Therapeutics, Inc.
FAQ
When will Spyre Therapeutics (SYRE) join the Nasdaq Biotechnology Index?
What criteria did Spyre Therapeutics (SYRE) meet to join the Nasdaq Biotechnology Index?
How often is the Nasdaq Biotechnology Index evaluated for company inclusion?
What is Spyre Therapeutics' (SYRE) main therapeutic focus?
